Department of Oncology

Latest Articles
Retrospective Study

A retrospective analysis of Estrogen Receptors in Breast Cancer and its comparison with national standards

Estrogen receptor (ER) positive tumours are more common than ER negative tumours and tend to have a better prognosis. These tumours respond well to endocrine therapy as compared to ER negative tumours, thus avoiding the harmful effects of chemotherapy. Moreover, since ER positive tumours are associated with slow tumour growth and low histology grade, it increases the overall survival.

DOI: https://www.doi.org/10.46766/thegms.oncol.22020601

View/Download
Review article

Male Breast Cancer: Another Look

Everybody is born with the mammary gland. Mammary gland development occurs through various stages throughout embryonic, and stays dormant for males. Although it is uncommon, male also gets breast cancer, occasionally. Male breast cancer accounts for approximately 1% of all breast cancer cases, and it is increasing. 

DOI: https://www.doi.org/10.46766/thegms.oncol.21040502

View/Download
Research article

ERCP in Bilio-pancreatic malignancy: Demographic profile among Bangladeshi patients

Outcome of most of the biliary and pancreatic malignancy is not good. Demography and involvement of different sites of these malignancies by endoscopic retrograde cholagiopancreatography (ERCP) are not widely studied in Bangladesh. 

DOI: https://www.doi.org/10.46766/thegms.oncol.21030603

View/Download
Case report

Primary Duodenal Adenocarcinoma: Case report and literature review

Primary adenocarcinoma of the duodenum is a rare clinical condition, accounting for only 5% of all gastrointestinal neoplasms and 0.5% of all intestinal neoplasms. Nonspecific clinical presentation contributes to the majority of cases being diagnosed in advanced stages. 

DOI: https://www.doi.org/10.46766/thegms.oncol.21012102

View/Download
Review article

Cancer management during COVID-19 period-A preliminary study

The ongoing COVID-19 pandemic has now thrown us into turmoil by adversely affecting the entire socio-economic structure of the world. Currently (Dec 20, 2020), there are 76.4 million incidences worldwide and 17.6 million in the USA, and counting. 

DOI: https://www.doi.org/10.46766/thegms.oncol.20122003

View/Download

Aims and Scope

The Department of Oncology publishes peer-reviewed; Open Access papers focusing on important advances and their relevance to cancer care. The Department communicates the results of clinical and experimental research within the fields of immunotherapy and chemotherapy. It provides state-of-the-art reviews on clinical and experimental therapies.

The Editors actively encourages Clinical aspects of basic research and trials that will have an impact on the understanding of health and disease. Case reports, focused research on a broad range of disciplines as well as experimental papers may be submitted. Besides, authors may contribute short reviews (by invitation from the Editor) and letters to the editor. This journal adheres to the policies recommended by The Committee on Publication Ethics (COPE).

The following subject areas are covered by Department of Oncology however the accepted papers are not constrained only to the listed areas.

  • Benign Tumors
  • Cancer Chemotherapy
  • Pediatric Oncology
  • Cancer prevention
  • Molecular biology
  • Tumor therapy
  • Radiation oncology
  • Apoptosis
  • Oncogenes
  • Angiogenesis
  • Metastasis
  • Tumor markers
  • Chemotherapy
  • Radiotherapy and biotherapy
  • Veterinary and Comparative Oncology
  • Clinical Trials in Oncology
  • Cancer Nanotechnology

Please direct any enquiry or submit papers to: info@thegms.co

error: Content is protected !!